HALOZYME THERAPEUTICS, INC. / HALO / ResearchSEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer
2026-09-02 2026-08-19 2026-08-18 2026-08-11 2026-08-06 2026-08-06 2026-07-09 2026-07-02 2026-07-02 2026-07-02 2026-07-02 2026-06-30 2026-05-11 2026-05-11 2026-05-07 2026-04-30 2026-04-24 2026-03-23 2026-03-12 2026-02-17 2026-02-17 2026-01-28 2025-12-09 2025-12-08 2025-11-24 2025-11-12 2025-11-07 2025-11-05 2025-11-03 2025-11-03 2025-10-14 2025-10-06 2025-10-03 2025-10-01 2025-08-05 2025-08-05 2025-05-06 2025-05-06 2025-05-02 2025-03-21 SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed
Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.
Transaction rows by code · counts, not monetary totals Purchase: 0 transaction rows 0 P Sale: 30 transaction rows 30 S Grant / award: 13 transaction rows 13 A Exercise / conversion: 22 transaction rows 22 M Tax / exercise payment: 1 transaction rows 1 F Gift: 0 transaction rows 0 G P · Purchase S · Sale A · Grant / award M · Exercise / conversion F · Tax / exercise payment G · Gift
66 matching transaction rows. Showing 51–66.
Transaction / filed Reporting owner Type Security Shares Reported price 2026-05-05 2026-05-07
Connaughton Bernadette A · Grant / awardAcquired
Common Stock 6796.0 0.0 2026-05-05 2026-05-07
Connaughton Bernadette A · Grant / awardAcquired
Option to Purchase Common StockDerivative security
6040.0 0.0 2026-05-01 2026-05-05
Connaughton Bernadette10b5-1 checkbox reported
S · SaleDisposed
Common Stock 1625.0 63.48 2026-04-06 2026-04-07
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 5900.0 63.14 2026-04-06 2026-04-07
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 4100.0 64.02 2026-04-06 2026-04-07
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionAcquired
Common Stock 10000.0 12.07 2026-04-06 2026-04-07
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionDisposed
Option to Purchase Common StockDerivative security
10000.0 12.07 2026-04-02 2026-04-02
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionAcquired
Common Stock 20000.0 12.07 2026-04-02 2026-04-02
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 4200.0 64.89 2026-04-02 2026-04-02
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 15800.0 64.06 2026-04-02 2026-04-02
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionDisposed
Option to Purchase Common StockDerivative security
20000.0 12.07 2026-04-01 2026-04-02
RAMSAY DAVID A A · Grant / awardAcquired
Restricted Stock UnitsDerivative security
10000.0 0.0 2026-04-01 2026-04-02
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionAcquired
Common Stock 20000.0 12.07 2026-04-01 2026-04-02
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 19000.0 65.36 2026-04-01 2026-04-02
Torley Helen10b5-1 checkbox reported
S · SaleDisposed
Common Stock 1000.0 65.71 2026-04-01 2026-04-02
Torley Helen10b5-1 checkbox reported
M · Exercise / conversionDisposed
Option to Purchase Common StockDerivative security
20000.0 12.07
Identity & relationships Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete
These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.
SEC issuer · 0001159036 HALOZYME THERAPEUTICS, INC.
No parent relationship is available in this import; this is not proof of independence.
Legal Entity Identifier 529900242I3SV9AGM753 GLEIF legal name HALOZYME THERAPEUTICS, INC. Entity / LEI registration status ACTIVE / ISSUED Reference data updated 2026-03-27T10:37:19Z direct-parent: no parent LEI supplied
ultimate-parent: no parent LEI supplied
GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records
Search names and former names View Wikidata identity and references ↗
Halozyme Therapeutics · alias · wikidata HALOZYME THERAPEUTICS INC · former SEC name · 2004-03-17 to 2019-07-03 GLOBAL YACHT SERVICES INC · former SEC name · 2001-09-21 to 2004-03-12 Explore headquarters map ↗ Revenue in constant purchasing power USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.
Year ended Reported USD revenue CPI-adjusted USD revenue 2024-12-31 $1.02B $1.08B 2023-12-31 $829.25M $908.71M 2022-12-31 $660.12M $753.07M 2021-12-31 $443.31M $546.20M 2020-12-31 $267.59M $345.25M 2019-12-31 $195.99M $255.97M 2018-12-31 $151.86M $201.94M 2017-12-31 $316.61M $431.30M
Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing
Explore the CPI history ↗